PLPBP
Pyridoxal phosphate homeostasis protein
Also known as: PLPHP_HUMAN, PROSC
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O94903
- Gene
- PLPBP
- Ensembl
- ENSG00000147471
- Chromosome
- 8
- Canonical length
- 275 aa
- Protein class
- Disease related genes, Human disease related genes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes a pyridoxal 5'-phosphate binding protein involved in the homeostatic regulation of intracellular pyridoxal 5'-phosphate. This gene has a tumor suppressive effect on hepatocellular carcinoma and other solid tumors of epithelial origin. Naturally occurring mutations in this gene are associated with a pyridoxine-dependent epilepsy. [provided by RefSeq, Mar 2017]
Canonical amino-acid sequenceUniProt
275 residues, UniProt reviewed canonical sequence.
>O94903|PLPBP
1 MWRAGSMSAE LGVGCALRAV NERVQQAVAR RPRDLPAIQP RLVAVSKTKP ADMVIEAYGH
61 GQRTFGENYV QELLEKASNP KILSLCPEIK WHFIGHLQKQ NVNKLMAVPN LFMLETVDSV
121 KLADKVNSSW QRKGSPERLK VMVQINTSGE ESKHGLPPSE TIAIVEHINA KCPNLEFVGL
181 MTIGSFGHDL SQGPNPDFQL LLSLREELCK KLNIPADQVE LSMGMSADFQ HAVEVGSTNV
241 RIGSTIFGER DYSKKPTPDK CAADVKAPLE VAQEHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PLPBP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 73 nTPM
Expression across tissuesHPA
Tissue
- liver: 73 nTPM
- kidney: 55 nTPM
- skeletal muscle: 47 nTPM
- colon: 44 nTPM
- tongue: 39 nTPM
- blood vessel: 39 nTPM
Single-cell type
- parietal cells: 88 nCPM
- endometrial luminal cells: 70 nCPM
- enterocytes: 69 nCPM
- hepatocytes: 67 nCPM
- kupffer cells: 66 nCPM
- hofbauer cells: 65 nCPM
Immune cell
- basophil: 165 nTPM
- non-classical monocyte: 148 nTPM
- eosinophil: 137 nTPM
- intermediate monocyte: 130 nTPM
- T-reg: 117 nTPM
- myeloid DC: 116 nTPM
Brain region
- white matter: 43 nTPM
- cerebral cortex: 41 nTPM
- choroid plexus: 41 nTPM
- hypothalamus: 38 nTPM
- cerebellum: 38 nTPM
- midbrain: 37 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PLPBP.
Disease | AllUniProt
Conditions PLPBP is implicated in, by any mechanism.
- Epilepsy, early-onset, 1, vitamin B6-dependent (EPEO1) MIM:617290
Disease | GeneticClinVar
23 pathogenic / likely-pathogenic of 297 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Epilepsy, early-onset, vitamin B6-dependent
- Inborn genetic diseases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.7
- gnomAD pLI
- 0.04
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 10% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- vitamin B6 metabolic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- PLP-binding barrel
- Alanine racemase, N-terminal
- Pyridoxal phosphate homeostasis protein
- Alanine racemase, N-terminal domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PLPBP as an antibody target. Whether an autoantibody or antibody against PLPBP could matter depends on whether native PLPBP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PLPBP is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PLPBP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...